DNAPrint Genomics, Inc. (DNAG/DNAG.PK) Wrap Up:

DNAPrint Genomics, Inc. engages in the research and development of genomic products, and provides scientific services and tests to the genealogy, forensic, pharmaceutical, and genetics markets in the United States. Its primary product under development is PT-401, a ‘Super EPO’ (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients. The company’s other products under development include PT-501 for the treatment of attention deficit hyperactivity disorder; PT-502 for the treatment of drug addiction; and PT-503 for the treatment of depression. DNAPrint Genomics also develops diagnostic tests, including OVANOME for ovarian cancer, STATINOME for the safety of statins, DIABETES-CD59 for pre-diabetes diabetic complications; and PONV for post-operative nausea and vomiting. In addition, it offers DNAWitness product suite for the forensics market to determine genetic heritage from DNA samples obtained from crime scenes; and ANCESTRYbyDNA and EURO-DNA, which are genealogy products that provide an inference of an individual's genetic ancestry or heritage. Further, the company provides sequencing and genotyping services to industrial customers. DNAPrint Genomics has strategic alliances with Moffitt Cancer Center, Bioserve Biotechnologies, Ltd., and Beth Israel Deaconess Medical Center; and a collaborative research agreement with Beth Israel. It also has a license agreement with Harvard Medical School, and a research sponsorship agreement with Massachusetts College of Pharmacy and Health Sciences. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida.